Additionally, another study on ER-positive breast cancer found that in cases of endocrine therapy resistance, reduced CSK leads to enhanced PAK2 activity and subsequent non-estrogen-dependent cancer growth (Xiao et al., 2018). The gene discussed is PAK2; the disease is cancer.